Ryan Cohlhepp sold $2,685 of BCAX
President and COO at Bicara Therapeutics Inc.. 149 shares at an average of $18.02, traded Jan 15, 2026, filed Jan 20, 2026.
Score components
- +20RolePresident
- 0Trade size$3k at market
- 0Share of holdings soldSold 0.1% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-002656, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | SOpen-market sale Common Stock10b5-1 | -149 | $18.02 | $2,685 | 213,992 | Jan 20, 2026 |
Related signals
Other insiders at Bicara Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 6Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President, COO & Interim CEO | $401k 17,500 shares | -9% | |
| 14Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $188k 9,200 shares | -6% | |
| 19Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $301k 15,000 shares | -4% | |
| 13Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $254k 12,500 shares | -6% | |
| 6Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $126k 5,500 shares | -9% | |
| 14Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $212k 9,200 shares | -6% | |
| 20Weak | Bicara Therapeutics Inc. | Claire Mazumdar Chief Executive Officer | $354k 15,000 shares | -4% | |
| 14Weak | Bicara Therapeutics Inc. | Ryan Cohlhepp President and COO | $288k 12,500 shares | -6% | |
| 5Weak | Bicara Therapeutics Inc. | David Raben Chief Medical Officer | $104k 5,500 shares | -9% | |
| 13Weak | Bicara Therapeutics Inc. | Ivan Hyep Chief Financial Officer | $170k 9,200 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.